Survivin -31G>C Polymorphism and Gastrointestinal Tract Cancer Risk: a Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Feb 14

PMID 23405077

Citations 10

Authors

Yan Liu

Lin Li

Haiyan Qi

Yan Gao

Sha Liu

Chongan Xu

Affiliations

Soon will be listed here.

Abstract

Background: Emerging evidence showed that common functional -31G>C polymorphism (rs9904341 G>C) in the promoter region of the survivin gene is involved in the regulation of survivin expression, thus increasing an individual's susceptibility to gastrointestinal tract (GIT) cancer; but individually published results are inconclusive. The aim of this systematic review and meta-analysis was to derive a more precise estimation of the association between survivin -31G>C polymorphism and GIT cancer risk.

Methods: A literature search of PubMed, Embase, Web of Science and CBM databases was conducted from inception through July 1st, 2012. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association.

Results: Nine case-control studies were included with a total of 2,231 GIT cancer cases and 2,287 healthy controls. The results indicated that survivin -31G>C polymorphism was associated with increased risk of GIT cancer. In the stratified analysis by cancer types, significant associations were observed between survivin -31G>C polymorphism and increased risk of colorectal and gastric cancers. However, the lack of association of survivin -31G>C polymorphism with esophageal cancer risk may be due to a lack of a sufficient number of eligible studies and the influence of different genetic and environmental factors.

Conclusion: Results from the current meta-analysis suggests that survivin -31G>C polymorphism might increase the risk of GIT cancer, especially among gastric and colorectal cancers.

Citing Articles

Influence of genetic polymorphism on sports talent performance versus non-athletes: a systematic review and meta-analysis.

Ferreira C, Silvino V, Trevisano R, de Moura R, Almeida S, Dos Santos M BMC Sports Sci Med Rehabil. 2024; 16(1):223.

PMID: 39482721 PMC: 11529235. DOI: 10.1186/s13102-024-01001-5.

Genetic polymorphisms and gastric cancer risk: a comprehensive review synopsis from meta-analysis and genome-wide association studies.

Tian J, Liu G, Zuo C, Liu C, He W, Chen H Cancer Biol Med. 2019; 16(2):361-389.

PMID: 31516756 PMC: 6713634. DOI: 10.20892/j.issn.2095-3941.2018.0290.

Survivin rs9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case-control studies.

Moazeni-Roodi A, Ghavami S, Hashemi M Int J Clin Oncol. 2019; 24(4):335-349.

PMID: 30747314 DOI: 10.1007/s10147-019-01408-y.

Evaluation of immunohistochemical expression of survivin and its correlation with -31G/C gene polymorphism in colorectal cancer.

Heidari Z, Mahmoudzadeh Sagheb H, Hakimi A, Moudi B Med Mol Morphol. 2018; 52(2):82-89.

PMID: 30128768 DOI: 10.1007/s00795-018-0204-0.

Association between common polymorphisms in ERCC gene and glioma risk: A meta-analysis of 15 studies.

Qian T, Zhang B, Qian C, He Y, Li Y Medicine (Baltimore). 2017; 96(20):e6832.

PMID: 28514298 PMC: 5440135. DOI: 10.1097/MD.0000000000006832.

References

Cheng Z, Hu L, Huang S . [Correlation of -31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma]. Ai Zheng. 2008; 27(3):258-63. View

Shoeneman J, Ehrhart 3rd E, Eickhoff J, Charles J, Powers B, Thamm D . Expression and function of survivin in canine osteosarcoma. Cancer Res. 2011; 72(1):249-59. DOI: 10.1158/0008-5472.CAN-11-2315. View

Antonacopoulou A, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos F, Marousi S . The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Anal Cell Pathol (Amst). 2010; 33(5):177-89. PMC: 4605658. DOI: 10.3233/ACP-CLO-2010-0537. View

Upadhyay R, Khurana R, Kumar S, Ghoshal U, Mittal B . Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol. 2010; 18(3):880-7. DOI: 10.1245/s10434-010-1371-y. View

Wang X, Huang L, Xu Y, Shi Z, Wang Y, Zhang J . Association between survivin -31G > C promoter polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet. 2012; 20(7):790-5. PMC: 3376263. DOI: 10.1038/ejhg.2011.276. View

Fukuda S, Pelus L . Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006; 5(5):1087-98. DOI: 10.1158/1535-7163.MCT-05-0375. View

Ikeguchi M, Kaibara N . survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer. 2002; 87(8):883-7. PMC: 2376173. DOI: 10.1038/sj.bjc.6600546. View

Song J, Maeng E, Cao Z, Kim S, Nam S, Lee J . The Glu346Lys polymorphism and frameshift mutations of the Methyl-CpG Binding Domain 4 gene in gastrointestinal cancer. Neoplasma. 2009; 56(4):343-7. DOI: 10.4149/neo_2009_04_343. View

Peters J, Sutton A, Jones D, Abrams K, Rushton L . Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006; 295(6):676-80. DOI: 10.1001/jama.295.6.676. View

10.

Srivastava K, Srivastava A, Mittal B . Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep. 2011; 39(2):1509-16. DOI: 10.1007/s11033-011-0889-9. View

11.

Yang L, Fang D, Wang R, Yang S . Effect of NF-kappaB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol. 2003; 10(1):22-5. PMC: 4717071. DOI: 10.3748/wjg.v10.i1.22. View

12.

Altieri D . The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 2001; 7(12):542-7. DOI: 10.1016/s1471-4914(01)02243-2. View

13.

Tu S, Jiang X, Lin M, Cui J, Yang Y, Lum C . Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 2003; 63(22):7724-32. View

14.

Yang X, Xiong G, Chen X, Xu X, Wang K, Fu Y . Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2009; 135(10):1341-9. DOI: 10.1007/s00432-009-0575-7. View

15.

Ambrosini G, Adida C, Sirugo G, Altieri D . Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998; 273(18):11177-82. DOI: 10.1074/jbc.273.18.11177. View

16.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

17.

Cui Y, Liu T, Zhuang R, Gao H, Li H . Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer. J Dig Dis. 2009; 10(2):118-23. DOI: 10.1111/j.1751-2980.2009.00373.x. View

18.

Nemoto T, Kitagawa M, Hasegawa M, Ikeda S, Akashi T, Takizawa T . Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol. 2004; 76(3):253-9. DOI: 10.1016/j.yexmp.2004.01.001. View

19.

Wang T, Qian X, Liu B . Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol. 2007; 13(20):2784-90. PMC: 4395628. DOI: 10.3748/wjg.v13.i20.2784. View

20.

Yagihashi A, Asanuma K, Nakamura M, Araya J, Mano Y, Torigoe T . Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem. 2001; 47(9):1729-31. View